NICE says no to Novartis’ Mayzent in secondary progressive MSThere isn’t enough evidence to back the use of Novartis Mayzent for secondary progressive multiple sclerosis on the Share XNICE says no to Novartis’ Mayzent in secondary progressive MShttps://pharmaphorum.com/news/nice-says-no-to-novartis-mayzent-in-secondary-progressive-ms/
Accessibility app wins Novartis multiple sclerosis innovation prizeCanadian start-up AccessNow has won first prize in a Novartis competition to find technological ways to help people Share XAccessibility app wins Novartis multiple sclerosis innovation prizehttps://pharmaphorum.com/news/accessibility-app-wins-novartis-multiple-sclerosis-innovation-prize/
Royalty Pharma plans largest IPO of the year so farRoyalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. Share XRoyalty Pharma plans largest IPO of the year so farhttps://pharmaphorum.com/news/royalty-pharma-plans-largest-ipo-of-the-year-so-far/
FDA extends review of Novartis’ MS drug ofatumumabThe FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed Share XFDA extends review of Novartis’ MS drug ofatumumabhttps://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/
BMS launches COVID-19 delayed MS drug Zeposia in USBristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA approval in Share XBMS launches COVID-19 delayed MS drug Zeposia in UShttps://pharmaphorum.com/news/bms-launches-covid-19-delayed-ms-drug-zeposia-in-us/
Novartis builds case for MS drug ofatumumab as FDA decision loomsNovartis has reported new data with its multiple sclerosis (MS) drug ofatumumab showing that it can suppress disease Share XNovartis builds case for MS drug ofatumumab as FDA decision loomshttps://pharmaphorum.com/news/novartis-builds-case-for-ms-drug-ofatumumab-as-fda-decision-looms/
BMS gets FDA nod for ozanimod, but launch will be delayedBristol-Myers Squibb’s multiple sclerosis therapy ozanimod has been approved by the FDA right on schedule, but the company Share XBMS gets FDA nod for ozanimod, but launch will be delayedhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-ozanimod-but-launch-will-be-delayed/
Macrophage Pharma goes for gold with new funding roundRichard Staines spoke with Soren Bregenholt, the new CEO of Macrophage Pharma, about the company’s strategy encompassing both Share XMacrophage Pharma goes for gold with new funding roundhttps://pharmaphorum.com/r-d/views-analysis-r-d/macrophage-pharma-goes-for-gold-with-new-funding-round/
Janssen files MS pill, ahead of FDA decision on BMS’ rivalJanssen has filed its ponesimod pill with the FDA for treatment of adults with relapsing multiple sclerosis, days Share XJanssen files MS pill, ahead of FDA decision on BMS’ rivalhttps://pharmaphorum.com/news/janssen-files-ms-pill-ahead-of-fda-decision-on-bms-rival/
